Oxford – October 2015
We are pleased to announce that Absolute Antibody and Ximbio have have agreed to terms allowing Absolute Antibody to recombinantly manufacture 13 of Ximbio’s classic antibodies. As part of this agreement, both partners will be able to market recombinant versions of the original antibodies, whilst Absolute Antibody will be generating a panel of additional variants to widen the field of potential applications for these antibodies.
We are very excited to be working together with Ximbio on this and hope that we can expand our collaboration in the future.
Over the years, researchers working for Cancer Research UK have generated many of the most widely used research antibodies.
Ximbio, formerly Cancer Research Technology, the development and commercialisation arm of Cancer Research UK, have been making these reagents available to the research community.
Through the antibody engineering and recombinant expression platform of Absolute Antibody, we hope to be generating new variants of these popular antibodies to meet the ever-growing standards of precise reagent definition and flexibility.